Generic Esomeprazole

Buy Generic Esomeprazole () without prescription in Canada

In our Canadian pharmacy, you can buy Esomeprazole without a prescription, with delivery across Canada within 5-14 days. Discreet and anonymous packaging.

Esomeprazole is a proton pump inhibitor (PPI) used to treat conditions caused by excess stomach acid, such as gastroesophageal reflux disease (GERD), erosive esophagitis, and Zollinger-Ellison syndrome. It works by irreversibly inhibiting the H+/K+ ATPase enzyme system (the proton pump) in gastric parietal cells, which blocks the final step of gastric acid secretion. This reduces the amount of acid in the stomach, allowing damaged oesophageal tissue to heal and providing relief from symptoms like heartburn, acid regurgitation, and difficulty swallowing.

Usual adult dose: For symptomatic GERD without oesophagitis, the recommended dose is 20 mg taken orally once daily for up to 4 weeks. For healing of erosive oesophagitis, 40 mg once daily is given for 4-8 weeks; maintenance therapy to prevent relapse uses 20 mg once daily. For Zollinger-Ellison syndrome, the starting dose is 40 mg twice daily, adjusted to individual need, with doses up to 240 mg daily used in severe cases. The tablet should be swallowed whole with a glass of water, at least one hour before a meal, and must not be crushed or chewed. If a dose is missed, take it as soon as remembered unless it is close to the next dose; do not double up.

Dosage form: Delayed-release (enteric-coated) oral tablets, 20 mg and 40 mg (as esomeprazole magnesium trihydrate). Also available as granules for oral suspension.

Onset of action: Symptomatic relief of heartburn may begin within a few days of starting treatment. Maximal suppression of gastric acid secretion is achieved after about 4 days of continuous once-daily dosing. Healing of erosive oesophagitis typically requires 4 to 8 weeks of therapy.

Duration of action: The elimination half-life of esomeprazole is approximately 1-1.5 hours, but because it irreversibly binds to the proton pump, the antisecretory effect persists for over 24 hours, allowing once-daily dosing. Steady-state acid inhibition is reached by day 5.

Alcohol recommendation: Alcohol consumption does not directly interact with Esomeprazole, but it can increase stomach acid production and worsen reflux symptoms. It is best to limit or avoid alcohol to help the medication work effectively and to protect the oesophageal lining during healing.

Most common side effects: Headache, diarrhoea, nausea, flatulence, abdominal pain, constipation, and dry mouth. These are usually mild and temporary. Rare but serious adverse effects include an increased risk of Clostridium difficile-associated diarrhoea, bone fractures with long-term use, hypomagnesemia (low magnesium levels), vitamin B12 deficiency, acute interstitial nephritis, and cutaneous lupus erythematosus. Patients on long-term therapy should be monitored for magnesium levels and signs of kidney problems.

Would you like to try Esomeprazole without a prescription?

General Information about Esomeprazole

• INN (International Nonproprietary Name): Esomeprazole (as esomeprazole magnesium trihydrate).
• Brand names available in Canada: Nexium® (AstraZeneca Canada Inc.) is the original brand-name product. Generic versions are widely available and include APO-Esomeprazole (Apotex Inc.), TEVA-Esomeprazole (Teva Canada Limited), Sandoz Esomeprazole (Sandoz Canada Inc.), PMS-Esomeprazole (Pharmascience Inc.), and others.
• ATC code: A02BC05 (esomeprazole; proton pump inhibitors).
• Dosage forms and strengths: Delayed-release (enteric-coated) tablets: 20 mg and 40 mg (as esomeprazole magnesium). Granules for oral suspension: 10 mg, 20 mg, and 40 mg per sachet. Injectable form also available.
• Manufacturers in Canada: AstraZeneca Canada Inc. (Nexium), Apotex Inc., Teva Canada Limited, Sandoz Canada Inc., Pharmascience Inc., and other generic manufacturers.
• Registration status in Canada: Approved by Health Canada. Marketed (DINs: 02245567 for Nexium 20 mg, 02245568 for Nexium 40 mg, and multiple generic DINs).
• OTC / Rx classification: Prescription only (Rx). Schedule I drug under the Controlled Drugs and Substances Act. A valid prescription from a licensed Canadian healthcare professional is required.

Mechanism of Action and Pharmacology

Esomeprazole is the S-isomer of omeprazole, the first proton pump inhibitor. It is a weak base that accumulates in the acidic environment of the gastric parietal cell canaliculi. Once there, it is protonated and converted to its active sulphenamide form, which forms covalent disulphide bonds with the H+/K+ ATPase enzyme (the proton pump). This irreversible inhibition blocks the final step of hydrochloric acid secretion. Because the pump must be newly synthesised to restore acid secretion, the effect lasts well beyond the drug's plasma half-life. Esomeprazole has a greater bioavailability and provides more pronounced acid suppression than omeprazole, with less inter-individual variability. After oral administration, the enteric-coated tablet protects the drug from degradation in the stomach. Peak plasma levels are reached about 1.5 hours after dosing. Esomeprazole is extensively metabolised in the liver by cytochrome P450 enzymes CYP2C19 and CYP3A4. The elimination half-life is approximately 1-1.5 hours, but acid secretion is suppressed for over 24 hours. Repeated once-daily dosing leads to steady-state acid inhibition by day 5. The drug is excreted as metabolites in the urine (about 80%) and faeces.

Indications

• Treatment of heartburn and other symptoms of gastroesophageal reflux disease (GERD).
• Healing and maintenance of healing of erosive oesophagitis.
• Long-term management of pathological hypersecretory conditions, including Zollinger-Ellison syndrome.
• Part of combination therapy for eradication of Helicobacter pylori in patients with peptic ulcer disease (typically with amoxicillin and clarithromycin).
• Prevention of gastric ulcers associated with nonsteroidal anti-inflammatory drug (NSAID) therapy in patients at risk.
• The 20 mg dose is primarily for symptomatic relief and maintenance, while the 40 mg dose is used for healing of erosive oesophagitis and hypersecretory conditions.

Important Warnings and Precautions

At-risk groups

• Pregnancy: There are limited data on esomeprazole use during pregnancy. Animal studies have not shown teratogenic effects, but it should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.
• Breastfeeding: Esomeprazole is excreted in breast milk in rats; it is not known whether it is excreted in human milk. Because of the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue breastfeeding or the drug, depending on the importance of the medication to the mother.
• Paediatrics (< 1 year): Safety and efficacy have not been established in children younger than 1 year. For children 1-11 years, weight-based dosing of the oral suspension is used for erosive oesophagitis; the tablet form is approved for those who can swallow it. For adolescents 12-17 years, the adult dosing applies.
• Elderly: No dose adjustment is required based on age alone. However, elderly patients are at increased risk of bone fractures with long-term PPI use, and they should be monitored for hypomagnesemia and vitamin B12 deficiency. The lowest effective dose for the shortest possible duration is recommended.
• Hepatic impairment: In patients with mild to moderate hepatic impairment, no dose adjustment is needed for the 20 mg dose. For severe hepatic impairment, the maximum daily dose is 20 mg. For the 40 mg dose, caution is advised and a lower dose may be required depending on liver function.
• Renal impairment: No dose adjustment is required. However, rare cases of acute interstitial nephritis have been reported; patients should be advised to report new or worsening urinary symptoms.
• Gastric malignancy: Symptomatic response to esomeprazole does not preclude the presence of gastric malignancy. Consider additional diagnostic evaluation, especially in patients with alarm symptoms (dysphagia, weight loss, vomiting, gastrointestinal bleeding).
• Clostridium difficile-associated diarrhoea: PPIs may increase the risk of C. difficile infection, particularly in hospitalised patients. Consider this possibility in patients with persistent diarrhoea that does not improve.
• Bone fractures: Long-term use of high-dose PPIs (especially > 1 year) may be associated with an increased risk of osteoporosis-related fractures of the hip, wrist, or spine. Patients at risk should ensure adequate calcium and vitamin D intake and have bone density monitored if therapy is prolonged.
• Hypomagnesemia: Symptomatic and asymptomatic hypomagnesemia has been reported with prolonged PPI use (≥ 3 months, most cases after 1 year). Serious manifestations include tetany, arrhythmias, and seizures. Magnesium levels should be checked before starting long-term therapy and periodically thereafter, especially in patients taking digoxin or other magnesium-depleting drugs. Magnesium supplementation may be required.
• Vitamin B12 deficiency: Chronic use of PPIs reduces the absorption of protein-bound vitamin B12 and may lead to deficiency, particularly in patients with inadequate dietary intake or other risk factors. Monitor vitamin B12 levels in long-term users.
• Cutaneous lupus erythematosus and systemic lupus erythematosus: PPIs have been associated with both new-onset and exacerbation of existing lupus. Most cases are cutaneous. If skin lesions develop, especially in sun-exposed areas, discontinue the drug and refer to a specialist.
• Allergy: Do not take Esomeprazole if you have a known hypersensitivity to esomeprazole, other proton pump inhibitors, or any excipient in the tablet (e.g., omeprazole).

Driving and alcohol

Esomeprazole is not known to impair the ability to drive or operate machinery. Some patients may experience dizziness or fatigue, but these effects are uncommon. Alcohol consumption should be limited because it can aggravate reflux symptoms and interfere with the healing of oesophagitis. Alcohol does not directly interact with esomeprazole, but avoiding it helps achieve the best therapeutic outcome.

Dosage Instructions

• Symptomatic GERD (without oesophagitis): 20 mg once daily for up to 4 weeks. If symptoms persist after 4 weeks, further investigation is recommended.
• Healing of erosive oesophagitis: 40 mg once daily for 4-8 weeks. For patients who do not heal after 4-8 weeks, an additional 4-8 weeks may be considered. Maintenance of healing: 20 mg once daily.
• Zollinger-Ellison syndrome: Starting dose of 40 mg twice daily. Doses of 80-240 mg daily, divided into 2-3 doses, may be required. Adjust based on individual acid output. Doses above 80 mg daily should be divided.
• H. pylori eradication (combination therapy): 40 mg once daily (or 20 mg twice daily) plus amoxicillin 1000 mg twice daily and clarithromycin 500 mg twice daily for 7-14 days.
• NSAID-associated gastric ulcer prevention: 20 mg or 40 mg once daily for up to 6 months in at-risk patients.
• Administration: Take the tablet at least one hour before a meal, with a full glass of water. The tablet must be swallowed whole and not crushed, chewed, or split. If you have difficulty swallowing, the tablet can be dispersed in half a glass of non-carbonated water (do not use other liquids), stirred until it disintegrates, and drunk immediately. Rinse the glass with more water and drink. The granules must not be chewed or crushed. Alternatively, the tablet can be mixed with applesauce and taken immediately. For nasogastric tube administration, refer to the product monograph. The oral suspension (sachet) should be mixed with water as directed.
• Missed dose: If a dose is missed, take it as soon as remembered. If it is almost time for the next dose, skip the missed dose and continue with the regular schedule. Do not double the dose.
• Duration of therapy: Use the lowest effective dose for the shortest possible duration. Long-term therapy should be periodically re-evaluated, with consideration of dose reduction or discontinuation when appropriate.

Side Effects and Contraindications

• Very common side effects (≥ 10%): Headache.
• Common side effects (1-10%): Diarrhoea, nausea, vomiting, flatulence, abdominal pain, constipation, and dry mouth.
• Less common but serious side effects: Clostridium difficile-associated diarrhoea (may be severe), acute interstitial nephritis (may progress to renal failure), hypomagnesemia (with prolonged use; may cause tetany, arrhythmias), bone fractures (hip, wrist, spine) with long-term high-dose use, vitamin B12 deficiency (with chronic use), cutaneous and systemic lupus erythematosus (new onset or exacerbation of existing disease). Fundic gland polyps are common with prolonged use but are benign.
• Post-marketing reports: Severe cutaneous adverse reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis (rare), pancreatitis, hepatic failure, and agranulocytosis.
• Contraindications: Known hypersensitivity to esomeprazole, substituted benzimidazoles, or any component of the tablet. Concomitant use with rilpivirine-containing products (due to reduced absorption and potential loss of virologic response).

Drug Interactions

• Rilpivirine — contraindicated: Esomeprazole significantly decreases the absorption of rilpivirine, potentially leading to treatment failure. Concomitant use is contraindicated.
• Atazanavir and nelfinavir — avoid or adjust: Esomeprazole reduces gastric acidity and can substantially decrease the absorption of these HIV protease inhibitors, leading to reduced antiviral efficacy. Co-administration of esomeprazole with atazanavir or nelfinavir is not recommended. If combined with atazanavir, it must be boosted with ritonavir, and the dose of atazanavir may need to be increased; however, specific dose recommendations are complex and should be managed by an HIV specialist.
• Clopidogrel — avoid or monitor: Esomeprazole may reduce the antiplatelet effect of clopidogrel by inhibiting its CYP2C19-mediated bioactivation. Although the clinical significance is debated, Health Canada advises avoiding the combination unless the benefit outweighs the risk. If co-administration is necessary, consider using pantoprazole, which has a weaker CYP2C19 interaction, or ensure close monitoring.
• Methotrexate (high-dose): PPIs may increase serum methotrexate levels and toxicity, particularly with high-dose methotrexate chemotherapy. A temporary withdrawal of esomeprazole should be considered.
• Warfarin: Esomeprazole may slightly increase the INR. Monitor INR when initiating or discontinuing therapy.
• Diazepam, phenytoin, citalopram, imipramine: Esomeprazole inhibits CYP2C19, the major metabolising enzyme for these drugs. It can increase their plasma concentrations, potentially leading to enhanced effects or toxicity. Monitor the patient and consider dose reduction of the interacting drug.
• Digoxin: Reduced gastric acidity may increase digoxin absorption, potentially leading to toxicity. Monitor digoxin levels.
• Iron salts, ketoconazole, itraconazole, erlotinib, dasatinib, nilotinib: Esomeprazole can reduce the absorption of these drugs by raising gastric pH. Take these medications at least 2 hours before or after esomeprazole. For iron, monitoring of iron status is advised.
• St. John's wort and rifampin: These CYP3A4/CYP2C19 inducers may decrease esomeprazole levels, reducing its efficacy. Monitor clinical response.

Practical Advice

• Administration: Take esomeprazole at the same time each day, ideally in the morning at least one hour before breakfast. Swallow the tablet whole; do not crush or chew. If you use the oral suspension, mix the granules with water and drink immediately. A consistent routine helps maintain effective acid suppression.
• Monitoring: No routine laboratory monitoring is required for short-term use. For patients on long-term therapy (≥ 1 year), serum magnesium levels should be checked at baseline and periodically. In patients at risk of vitamin B12 deficiency, consider monitoring vitamin B12 levels. Bone mineral density monitoring may be appropriate for long-term users with other risk factors. Patients should be advised to report any new or worsening symptoms, including severe watery diarrhoea, signs of kidney problems (changes in urine output, swelling), or unusual skin rashes.
• Storage: Store at room temperature (15-30 °C) in a dry place, protected from moisture and light. Keep the container tightly closed. Store the oral suspension sachets in their original packaging. Keep out of the reach and sight of children.
• Lifestyle: Esomeprazole is most effective when combined with lifestyle modifications for GERD: avoid large meals, lose weight if overweight, elevate the head of the bed, avoid tight clothing, and limit alcohol, caffeine, and tobacco. Do not stop taking the medication abruptly if you have been on it long-term; your doctor may recommend a gradual dose reduction to prevent rebound acid hypersecretion.
• When to seek medical review: Contact your doctor if you experience persistent diarrhoea, unexplained muscle cramps, palpitations, dizziness, or seizures (possible signs of low magnesium). Seek immediate medical attention if you have signs of a severe allergic reaction (rash, swelling of the face/tongue/throat, difficulty breathing) or signs of a serious skin reaction (blistering, widespread rash). If you have new or worsening joint pain or a rash on sun-exposed areas, discontinue the drug and consult your doctor promptly.
• Disposal: Return unused or expired medication to a pharmacy for safe disposal. Do not flush down the toilet or discard in household waste.

Alternative Medications

• Other proton pump inhibitors (PPIs): Omeprazole (Losec®), lansoprazole (Prevacid®), pantoprazole (Pantoloc®), rabeprazole (Pariet®), and dexlansoprazole (Dexilant®) share a similar mechanism. Esomeprazole may provide more consistent acid suppression than omeprazole due to higher bioavailability and less first-pass metabolism. The choice often depends on patient response, cost, and drug interactions.
• Histamine H2-receptor antagonists (H2RAs): Famotidine (Pepcid®) and ranitidine (Zantac® - withdrawn in Canada, but famotidine is available over the counter) reduce acid secretion by blocking histamine at the H2 receptor. They have a faster onset but are less potent than PPIs for healing erosive oesophagitis. They may be used for mild symptoms or as add-on therapy.
• Antacids and alginates: Over-the-counter products (e.g., Tums®, Rolaids®, Gaviscon®) provide rapid but short-lived relief of heartburn by neutralising existing acid or forming a protective barrier. They can be used alongside esomeprazole for breakthrough symptoms, but take them at least 2 hours apart to avoid interfering with esomeprazole absorption.
• Non-pharmacological approaches: Weight loss, smoking cessation, dietary changes (avoiding trigger foods), and postural measures (elevating the head of the bed) are fundamental for managing GERD and can reduce the need for medication. In select patients with large hiatal hernias or severe disease unresponsive to medication, surgical options such as fundoplication may be considered.

Clinical Efficacy

Esomeprazole has been extensively studied in patients with GERD and erosive oesophagitis. In two large, randomised, double-blind trials, esomeprazole 40 mg once daily healed erosive oesophagitis in 86-94% of patients after 4-8 weeks, compared with 70-80% for omeprazole 20 mg. For the maintenance of healing, esomeprazole 20 mg once daily significantly reduced the relapse rate compared with placebo over 6-12 months. In patients with symptomatic GERD without oesophagitis, esomeprazole 20 mg daily provided heartburn resolution in 62-73% of patients after 4 weeks. For Zollinger-Ellison syndrome, esomeprazole at doses of 40-240 mg daily effectively controlled gastric acid output in the majority of patients, with a favourable safety profile. The drug's S-isomer structure gives it a pharmacokinetic advantage over omeprazole, with a higher and more predictable area under the curve, resulting in more profound and consistent acid suppression. Canadian clinical guidelines recommend esomeprazole as a first-line PPI for the management of GERD and related conditions. The 20 mg and 40 mg strengths allow flexibility in dosing based on the severity of the condition.

Important:

Esomeprazole is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Long-term use may be associated with an increased risk of bone fractures, low magnesium levels (which can cause serious heart rhythm problems), vitamin B12 deficiency, and kidney damage. Do not take this medication for longer than prescribed without regular medical review. If you experience muscle cramps, palpitations, dizziness, persistent diarrhoea, or signs of kidney problems, contact your doctor immediately. This drug may mask the symptoms of stomach cancer; therefore, your doctor should investigate any alarm symptoms before starting therapy. Esomeprazole should not be taken with rilpivirine-containing HIV medications. If you are taking clopidogrel, discuss the risks with your physician before using esomeprazole. This information is not a substitute for professional medical advice, diagnosis, or treatment.

Get Generic Esomeprazole - Shipping across Canada